For over forty years, patients seeking hair restoration without daily scalp ointments have resorted to cutting up high-dose generic blood pressure tablets off-label. However, immediate-release minoxidil pills dump active drug into the bloodstream within 60 minutes, risking reflex tachycardia (rapid heartbeat), lightheadedness, fluid retention, and sudden drops in blood pressure.
In this randomized, double-blind, placebo-controlled trial evaluating 536 men across 52 weeks, VDPHL01 demonstrated statistically significant hair count separation from placebo as early as Month 2. By Month 6, up to 68.7 percent of patients achieved visible hair coverage improvement on standardized clinical scales, while the modified-release matrix kept peak drug levels smooth, delivering robust hair regrowth without the cardiovascular spikes that plague conventional generic pills.
What Is It and How Does It Work?
The therapeutic mechanism centers on Pharmacokinetic Peak-Flattening, Sustained Follicular Sulfotransferase Bio-Activation, and Membrane Hyperpolarization—maintaining continuous drug delivery to the hair follicle root without overwhelming the heart or blood vessels.
-
The Problem with Crushed Immediate-Release Pills: When someone swallows a generic blood pressure tablet containing immediate-release minoxidil, the medication dissolves rapidly in the stomach. This produces an abrupt, high peak concentration ($C_{\max}$) in the bloodstream within an hour. This sudden surge violently dilates peripheral arteries, causing blood pressure to dip and triggering the nervous system to force a rapid heartbeat (reflex tachycardia) and fluid pooling in the ankles.
-
The Extended-Release Hydrophilic Matrix: Developed by Veradermics, VDPHL01 is formulated with a calibrated hydrophilic polymer matrix. As fluid enters the tablet in the digestive tract, it forms a microscopic gel layer that steadily releases micro-doses of minoxidil over a prolonged 12-to-24-hour dissolution curve. This flattens the sharp blood concentration spike, keeping drug levels well beneath the threshold that triggers cardiac symptoms.
-
Follicular Sulfotransferase Conversion: Once steady levels circulate to the scalp, minoxidil diffuses into the follicular infundibulum and dermal papilla. There, the local enzyme sulfotransferase (SULT1A1) metabolizes the prodrug into its biologically active form, minoxidil sulfate.
-
Opening ATP-Sensitive Potassium Channels: Minoxidil sulfate binds directly to ATP-sensitive potassium ($K_{\text{ATP}}$) channels located on cell membranes within hair follicle dermal papilla cells and surrounding capillary smooth muscle. The resulting potassium ion efflux hyperpolarizes the cell membranes, keeping calcium out, relaxing microvascular tone, and triggering quiescent hair follicle stem cells to exit dormancy and transition into prolonged active growth (anagen).
The Science: Clear Results from the 536-Patient Phase 3 Study 304
The multi-center, randomized, double-blind, placebo-controlled Phase 3 trial evaluated 536 adult men with mild-to-moderate androgenetic alopecia over 52 weeks (featuring a 6-month primary placebo-controlled period followed by an open-label safety extension):
-
Significant Separation as Early as Month 2: High-resolution phototrichograms and clinical assessments demonstrated statistically significant superiority over placebo in target area hair count (TAHC), patient-reported outcomes (PRO), and investigator global assessments (IGA) at Month 2—the earliest evaluation window in the trial.
-
Up to 68.7% Achieve Meaningful Hair Coverage Gains: On the co-primary endpoint measuring the proportion of participants achieving “improved” or “much improved” hair coverage on the Androgenetic Alopecia Impact Rating Scale (AAIRS), 55.7 percent of once-daily patients and 68.7 percent of twice-daily patients met the threshold, compared to only 15.0 percent in the placebo cohort ($p < 0.0001$).
-
Replication of High-Density Regrowth: The results confirmed findings from the preceding 519-patient Study 302, where active treatment drove non-vellus hair count increases of 30.3 to 33.0 hairs per square centimetre from baseline, outperforming placebo by more than four-fold.
-
Cardiovascular Safety Matching Placebo: Ambulatory blood pressure monitoring and serial electrocardiograms (ECGs) confirmed that avoiding the sharp plasma peak eliminated the tachycardia and hypotension associated with off-label generic minoxidil, yielding hemodynamic adverse event rates comparable to the inactive vehicle.
“The VDPHL01 results are encouraging and give us reason to expect more from treatment. If approved, VDPHL01 could give physicians greater confidence to bring up hair loss, offer treatment, and help more patients see a meaningful improvement in their pattern hair loss.”— Clinical Investigator Consortium, Veradermics Phase 3 Study 304 Report.
When Will It Be Available?
-
Current Stage: Completed pivotal Phase 3 registration testing in men (Study 304, NCT06972264); companion Phase 2/3 registration trial in 556 women with female pattern hair loss (Study 306, NCT07146022) is actively running.
-
Timeline: Topline data from the female registration program will read out in the first half of 2027. With two positive Phase 3 trials in men completed, New Drug Application (NDA) submissions to the US FDA and European regulatory bodies are scheduled for 2027, pointing toward commercial prescription pharmacy availability by late 2027 to 2028.
How you can benefit from this treatment now
-
A Dedicated Oral Pill for Pattern Hair Loss: This milestone confirms that hair medicine is shifting away from unapproved, cut-up blood pressure pills toward FDA-calibrated, extended-release tablets formulated specifically for scalp hair density.
-
Discuss Micro-Dose Splitting with Your Doctor: If you currently take off-label immediate-release oral minoxidil (such as 2.5 mg or 5 mg) and experience lightheadedness, morning fatigue, or heart racing, ask your prescribing physician whether dividing your daily dose into smaller morning and evening portions (e.g., 1.25 mg twice daily) helps smooth out the drug peak until extended-release pills arrive.
-
Support Native Scalp Sulfotransferase Activity: Oral minoxidil still requires the enzyme sulfotransferase (SULT1A1) in the scalp and liver to work; incorporating weekly 0.5 mm shallow scalp micro-stamping or physician-guided topical retinoids helps support localized enzyme activity and follicular permeability.
-
Check Baseline Heart Health Before Starting Oral Regimens: Because potassium-channel openers affect vascular tone, obtain a baseline blood pressure check and resting heart rate measurement with your doctor before taking any oral hair regrowth medication.
-
Avoid Compounded “Slow-Release” Capsules Online: Do not buy unregulated compounded capsules claiming to be extended-release from online telehealth websites; genuine modified-release dissolution curves require calibrated pharmaceutical matrices, whereas generic compounding often dumps the active drug immediately.
Action: If you currently take oral minoxidil, check your resting heart rate and blood pressure 60 minutes after taking your dose to ensure you are not experiencing symptomless cardiovascular spikes while awaiting commercial extended-release formulations.